Merck KGaA (OTCMKTS:MKGAY) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Merck KGaA (OTCMKTS:MKGAYGet Rating) have received an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $252.50.

Separately, Jefferies Financial Group assumed coverage on shares of Merck KGaA in a research note on Monday, July 25th. They set a “buy” rating for the company.

Merck KGaA Price Performance

MKGAY stock opened at $38.36 on Tuesday. Merck KGaA has a 12 month low of $32.53 and a 12 month high of $42.02. The company has a 50-day moving average price of $38.36 and a 200 day moving average price of $38.36.

About Merck KGaA

(Get Rating)

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.

Further Reading

Analyst Recommendations for Merck KGaA (OTCMKTS:MKGAY)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.